Christine Marie Dela Cruz

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim et al. · Journal of Clinical Oncology · 2019 · 230 citations

Medicine, Oncology, Pharmacology +15

Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

Anthony B. El-Khoueiry, Ignacio Melero, Todd S. Crocenzi et al. · Journal of Clinical Oncology · 2015 · 196 citations

Medicine, Oncology, Pharmacology +14

Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.

Masatoshi Kudo, Ana Matilla, Armando Santoro et al. · Journal of Clinical Oncology · 2019 · 98 citations

Medicine, Oncology, Pharmacology +14

Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.

Todd S. Crocenzi, Anthony B. El-Khoueiry, Thomas Cheung Yau et al. · Journal of Clinical Oncology · 2017 · 87 citations

Medicine, Oncology, Pharmacotherapy +17

A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

Bruno Sangro, Joong‐Won Park, Christine Marie Dela Cruz et al. · Journal of Clinical Oncology · 2016 · 60 citations

Pharmacy, Oncology, Pharmacology +17